» Articles » PMID: 20038306

[Expressions of Osteopontin and B7-H4 in Epithelial Ovarian Neoplasm and Their Significance]

Overview
Journal Chin J Cancer
Publisher Biomed Central
Specialty Oncology
Date 2009 Dec 30
PMID 20038306
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Epithelial ovarian cancer involves a number of factors. Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer. B7-H4 is a newly identified tumor marker in ovarian cancer. This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.

Methods: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.

Results: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05). The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05). The positive rate of OPN associated with a higher rate of lymph node metastasis (P<0.05), but did not relate to age and histologic type. The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.

Conclusion: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.

Citing Articles

Osteopontin as a Tumor Marker in Ovarian Cancer.

Rani S, Sehgal A, Kaur J, Pandher D, Punia R J Midlife Health. 2023; 13(3):200-205.

PMID: 36950209 PMC: 10025823. DOI: 10.4103/jmh.jmh_52_22.


Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.

Podojil J, Glaser A, Baker D, Courtois E, Fantini D, Yu Y Oncoimmunology. 2020; 9(1):1744897.

PMID: 32363111 PMC: 7185218. DOI: 10.1080/2162402X.2020.1744897.


Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.

Guo J, Yang W, Pak D, Celestino J, Lu K, Ning J Cancers (Basel). 2019; 11(5).

PMID: 31035430 PMC: 6562667. DOI: 10.3390/cancers11050596.


Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis.

Ye Y, Wang J, Li S, Wang S, Jing F Medicine (Baltimore). 2018; 97(32):e11821.

PMID: 30095655 PMC: 6133395. DOI: 10.1097/MD.0000000000011821.


Potential targeting of B7-H4 for the treatment of cancer.

Podojil J, Miller S Immunol Rev. 2017; 276(1):40-51.

PMID: 28258701 PMC: 5630270. DOI: 10.1111/imr.12530.